631 related articles for article (PubMed ID: 33429412)
1. Two new doses of dulaglutide (Trulicity) for diabetes.
Med Lett Drugs Ther; 2020 Oct; 62(1609):168. PubMed ID: 33429412
[No Abstract] [Full Text] [Related]
2. Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
Pace E; Tingen J
Am Fam Physician; 2017 Oct; 96(8):540-542. PubMed ID: 29094890
[No Abstract] [Full Text] [Related]
3. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
[TBL] [Abstract][Full Text] [Related]
4. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.
Shi LX; Liu XM; Shi YQ; Li QM; Ma JH; Li YB; Du LY; Wang F; Chen LL
J Diabetes Investig; 2020 Jan; 11(1):142-150. PubMed ID: 31102326
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
[TBL] [Abstract][Full Text] [Related]
7. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
[TBL] [Abstract][Full Text] [Related]
8. [Dulaglutide and liraglutide compared].
Bruhn C
Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
[No Abstract] [Full Text] [Related]
9. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
10. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
[TBL] [Abstract][Full Text] [Related]
11. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Thompson AM; Trujillo JM
Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
[TBL] [Abstract][Full Text] [Related]
12. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.
Boustani MA; Pittman I; Yu M; Thieu VT; Varnado OJ; Juneja R
Diabetes Obes Metab; 2016 Aug; 18(8):820-8. PubMed ID: 27161178
[TBL] [Abstract][Full Text] [Related]
13. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Gerstein HC; Hart R; Colhoun HM; Diaz R; Lakshmanan M; Botros FT; Probstfield J; Riddle MC; Rydén L; Atisso CM; Dyal L; Hall S; Avezum A; Basile J; Conget I; Cushman WC; Hancu N; Hanefeld M; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Muñoz EGC; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
Lancet Diabetes Endocrinol; 2020 Feb; 8(2):106-114. PubMed ID: 31924562
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
Guo L; Xi Y; Li L; Guo K; Wu J; Xu J; Wang Y; Wu G; Si S
Diabetes Obes Metab; 2024 Jul; 26(7):2979-2983. PubMed ID: 38600796
[No Abstract] [Full Text] [Related]
15. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
[TBL] [Abstract][Full Text] [Related]
16. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
17. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
